NCT03007498

Brief Summary

Check the safety under normal conditions of use through the verification of emergence signs of irritability and sensitisation of the genital mucosa.

Trial Health

50
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
55

participants targeted

Target at P25-P50 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 29, 2016

Completed
3 days until next milestone

Study Start

First participant enrolled

January 1, 2017

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 2, 2017

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2017

Completed
Last Updated

January 2, 2017

Status Verified

December 1, 2016

Enrollment Period

1 month

First QC Date

December 29, 2016

Last Update Submit

December 29, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Evaluation of adverse effects in maximized conditions

    60 days

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with age from 18 to 70 years old, with skin color varying between clear caucasian to dark.

You may qualify if:

  • Age between 18 to 70 years old;
  • Skin types: I (light caucasian), II (caucasian), III (light dark) and IV (dark)
  • intact skin where the product will be applied
  • Agreement to comply with the test procedures and attend the clinic in the days and ixed times for medical assessments and application and reading of dressings
  • Signature of informed consent form

You may not qualify if:

  • Pregnancy and lactation
  • Use of anti-inflammatory and immunosuppressive drugs from 30 days up to three months prior to selection;
  • Diseases that cause immune suppression;
  • Personal history of atopy;
  • History of sensitisation and irritability to topical products;
  • Active cutaneous pathologies (local and / or scattered) that may interfere in the study results;
  • Use of new drugs and/or cosmetics during the experiment;
  • Skin reactivity;
  • Previous participation in a study with the same product under test;
  • Volunteers who have congenital or acquired known immunodeficiency;
  • Relevant medical history or current evidence of alcohol or other drugs abuse;
  • Known historical or suspected intolerance to any ingredient of the product under study (product under test or comparator);
  • Sponsor's employees involved in the study, or close family member of an employee involved in the study;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Design

Study Type
observational
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 29, 2016

First Posted

January 2, 2017

Study Start

January 1, 2017

Primary Completion

February 1, 2017

Last Updated

January 2, 2017

Record last verified: 2016-12